Overview
- 37 inspections across 36 sites are on record.
- 1 Form 483 observation is attributed to this investigator.
- Most recent recorded activity is 2026-04-17.
At a glance
Inspections
37
Sites
36
Observations
1
Career since
Nov 2013
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Novo Nordisk A/S | 17 Apr 2026 | Human Drugs | On file |
| Hanlim Pharm Co. Ltd. | 10 Apr 2026 | Human Drugs | |
| Shanghai Xihua Scientific Co. Ltd. | 6 Feb 2026 | Human Drugs | |
| Labcorp Development (Asia) Pte. Ltd | 30 Jan 2026 | Human Drugs | On file |
| Janssen Pharmaceutica, N.V. | 5 Sep 2025 | Human Drugs | On file |
Sites inspected
Novo Nordisk A/SMalov, Denmark1 insp.
Hanlim Pharm Co. Ltd.Yongin, Korea (the Republic of)1 insp.
Shanghai Xihua Scientific Co. Ltd.Shanghai, China1 insp.
Labcorp Development (Asia) Pte. LtdSingapore, Singapore1 insp.
Janssen Pharmaceutica, N.V.Beerse, Belgium1 insp.
Co-investigators
Investigators who share inspections with this person.
Gajendiran Mahadevan5 shared
Young M Choi4 shared
Li-Hong P Yeh3 shared
Nicola M Fenty-Stewart3 shared
Kirtida Patel3 shared
Xingfang Li2 shared
Li-Hong Yeh2 shared
Vickie J Kanion2 shared
Yiyue Zhang2 shared
Lakecha N Lewis2 shared
Full investigator report
Get the verbatim findings behind Ruben C Ayala's 1 observation
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site